Figure and Table | Usefulness of the G8 Geriatric Assessment Tool as a Prognostic Factor in Gemcitabine Plus Nab-paclitaxel Combination Therapy for Elderly Patients with Pancreatic Cancer

Table 1. G8 Geriatric Assessment Tool.

Item	Score
1. Has food intake declined over the past 3 months due to loss of appetite, digestive problems, chewing, or swallowing difficulties?	0 = severe decrease in food intake
	1 = moderate decrease in food intake
	2 = no decrease in food intake
2. Weight loss during the last 3 months?	0 = weight loss >3 kg
	1 = does not know
	2 = weight loss between 1 and 3 kg
	3 = no weight loss
3. Mobility?	0 = bed or chair bound
	1 = able to get out of bed/chair
	but does not go out
	2 = goes out
4. Neuropsychological problems?	0 = severe dementia or depression
	1 = mild dementia
	2 = no psychological problems
5. Body mass index?	0 = BMI <19
	1 = BMI 19 to <21
	2 = BMI 21 to <23
	3 = BMI ≥23
6. Takes more than three prescription drugs per day?	0 = yes
6. Takes more than three prescription drugs per day?	1 = no
7. In comparison with other people of the same age, how does the patient consider his/her health status?	0.0 = not as good
	0.5 = does not know
	1.0 = as good
	2.0 = better
8. Age	0: >85
	1: 80-85
	2: <80
Total score	0-17

Table 2. Patient Characteristics.

Category		N (%) (n = 77)
Gender (%)
	Male	47 (61)
	Female	30 (39)
Age at chemotherapy (years)
	Median (range)	72 (65-91)
ECOG performance status
	0	67 (87)
	1	10 (13)
Body mass index
	Median (range)	21.2 (17.2-30.5)
Disease status
	Locally advanced	21 (27.3)
	distant metastasis	56 (72.7)
Metastatic site
	Liver	35 (45.5)
	Peritoneum	15 (19.5)
	Number of metastatic sites 2≥	22 (28.6)
G8 geriatric screening
	Median (range)	10.5 (6.5-15.5)
	≤10	34 (44.2)
	≥10.5	43 (55.8)
Geriatric nutrition risk index
	Median (range)	97.4 (75.8-114.5)
	≤86	66 (85.7)
	>86	11 (14.3)
Neutrophil-lymphocyte ratio
	Median (range)	2.66 (0.72-13.6)
	<3.9	65 (84.4)
	≥3.9	12 (15.6)
Modified Glasgow Prognostic Score
	0	59 (76.6)
	1-2	18 (23.4)
Carcinoembryonic antigen (ng/ml)
	<5.0	36 (46.8)
	≥5.0	41 (53.2)
Carbohydrate antigen 19-9 (U/ml)
	<37.0	20 (26)
	≥37.0	57 (74)

Table 3. Univariate and Multivariate Analyses to Detect Independent Prognostic Factors.

		Survival	Univariate	Multivariate
Variable	n	month	p value	HR (95%CI)	p value
Gender
Male	47	10.0	0.50
Female	30	13.8	0.50
ECOG performance status
0	67	13.0	0.009	3.00(1.15-7.82)	0.02
1	10	8.1	0.009	3.00(1.15-7.82)	0.02
Disease status
Locally advanced	21	13.5	0.12
Distant metastasis	56	11.2	0.12
G8 geriatric screening
<10.5	30	8.0	<0.001	5.38 (2.76-10.5)	*<0.001*
≥10.5	47	18.5	<0.001	5.38 (2.76-10.5)	*<0.001*
GNRI
<86	11	8.1	0.05	0.63 (0.29-1.39)	0.26
≥86	66	13.0	0.05	0.63 (0.29-1.39)	0.26
Initially reduced dose of GnP
Yes	23	9.0	0.02	1.55 (0.86-2.80)	0.14
No	54	13.5	0.02	1.55 (0.86-2.80)	0.14
NLR
<3.9	65	13.0	0.005	2.72 (1.11-6.68)	*0.03*
≥3.9	12	7.6	0.005	2.72 (1.11-6.68)	*0.03*
mGPS
0	59	13.5	0.04	1.62 (0.81-3.26)	0.18
1-2	18	8.0	0.04	1.62 (0.81-3.26)	0.18
CEA (ng/ml)
<5.0	36	13.0	0.09
≥5.0	41	11.0	0.09
CA19-9 (U/ml)
<37.0	20	14.6	0.79
≥37.0	57	11.5	0.79